Clinical Trial

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The overall goal of this first-in-human (FIH) clinical trial is to learn about the safety and dosing of COM503 when given alone or in combination with zimberelimab in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of COM503 as monotherapy and COM503 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of COM503 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-12-29; most recent amendment 2026-02-26.
Trial Details
NCT Number NCT06759649
Lead Sponsor Compugen Ltd
Collaborators: Gilead Sciences
Conditions Neoplasm, Cancer, Malignant Tumors
Enrollment 200 participants
Start Date 2025-01-07
Primary Completion 2027-11-22 (estimated)
Study Completion 2027-11-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-12